Adapted radiation with chemotherapy before rectal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new way of delivering radiation therapy for rectal cancer before surgery. It aims to see if adapting the radiation based on how the tumor shrinks can be more effective and safer than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of rectal cancer (adenocarcinoma) that has not spread to other organs.
- Your tumor must be 'microsatellite stable' (a genetic feature that doctors check).
- You must be 18 to 80 years old and in reasonably good general health.
- You must not have had prior chemotherapy or radiation to the pelvic area.
- You may need to have a special MRI scan to see if your tumor shrinks enough during the first part of treatment to qualify for the second part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that uses real-time MRI imaging to adjust the radiation precisely to your tumor. It is designed to improve the accuracy of treatment for locally advanced rectal cancer, potentially reducing damage to nearby healthy tissue.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
This trial tests giving radiation, chemotherapy, and immunotherapy before surgery for rectal cancer that has not spread far. The goal is to see if this combination shrinks the tumor more and improves outcomes before surgery.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.